Last reviewed · How we verify
NCT04165681
A Mobile and Virtual Reality Intervention for Adolescent Depression
NA trial testing Limbix Spark in Depression in 30 participants. Completed in 17 April 2020.
19 March 2020
Quick facts
| Lead sponsor | Limbix Health, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 12 October 2019 |
| Primary completion | 19 March 2020 |
| Estimated completion | 17 April 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Limbix Spark
Conditions studied
- Depression — all drugs for Depression →
Sponsor
Limbix Health, Inc.
Who can join
Adults 12 to 21, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depression, the most common mental health disorder among adolescents, is a critical health problem within the US. In this study, the feasibility, acceptability, and preliminary efficacy of Limbix Spark, a cognitive behavioral therapy (CBT)- based mobile app + virtual reality (VR) program for helping adolescents live well with depression will be investigated. This program is specifically designed around behavioral activation theory, the idea that completing activities that make a patient feel pleasure or provide a sense of mastery are effective in reducing symptoms of depression. The program involves the use of both VR and a mobile app that include CBT components like psychological assessments, psychoeducation, and skills training. 30 participants aged 12-21 years old with mild to severe depressive symptoms and smartphone access will be enrolled in this study. The primary efficacy outcome measures will be depressive symptoms with anxiety symptoms, functional outcomes, and dimensional scales of positive and negative affect and behavioral activation serving as secondary outcome measures. Qualitative and quantitative feedback on the use of the VR + mobile app (ease of use, comfort, willingness to use again) will be assessed using questionnaires. Engagement and adherence to the program will be assessed by assessing VR and app usage.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Self-Guided Digital Intervention for Depression in Adolescents: Feasibility and Preliminary Efficacy Study.
Miller I, Peake E, Strauss G, Vierra E, et al · · 2023 · cited 10× · PMID 37991839 · DOI 10.2196/43260
Verify or expand the search:
- PubMed search for NCT04165681
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Limbix Spark
Trials testing the same drug.
- NCT04524598 — A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19 · NA · completed
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other Limbix Health, Inc. trials
Trials by the same sponsor.
- NCT05351866 — Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management · NA · terminated
- NCT05461599 — Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology · NA · terminated
- NCT05462652 — Self-guided Treatment for Adolescents Navigating Depression · NA · completed
- NCT04524598 — A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04165681 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Limbix Health, Inc.
- Last refreshed: 7 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04165681.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing